4basebio PLC
88Q
Company Profile
Business description
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
Contact
25 Norman Way
Over
CambridgeCB24 5QE
GBRT: +44 1223967943
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
110
Stocks News & Analysis
stocks
Expense concerns for ASX best idea
Expense guidance changes short-term earnings but not long-term fundamentals.
stocks
Chart of the Week: Australian asset managers face structural pressure
Read the latest take from our analysts.
stocks
Going into earnings, is Alphabet a buy, a sell, or fairly valued?
From cloud computing growth to AI monetization, here’s what we’re looking for in Alphabet’s upcoming earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,250.60 | 50.70 | -0.55% |
| CAC 40 | 8,066.68 | 86.14 | -1.06% |
| DAX 40 | 24,822.79 | 71.65 | -0.29% |
| Dow JONES (US) | 49,015.60 | 12.19 | 0.02% |
| FTSE 100 | 10,154.43 | 53.37 | -0.52% |
| HKSE | 27,826.91 | 699.96 | 2.58% |
| NASDAQ | 23,857.45 | 40.35 | 0.17% |
| Nikkei 225 | 53,358.71 | 25.17 | 0.05% |
| NZX 50 Index | 13,414.35 | 1.48 | 0.01% |
| S&P 500 | 6,978.03 | 0.57 | -0.01% |
| S&P/ASX 200 | 8,933.90 | 40.40 | -0.45% |
| SSE Composite Index | 4,151.24 | 11.33 | 0.27% |